RCT | Mepolizumab for urban children with exacerbation-prone eosinophilic asthma.
22 Aug, 2022 | 12:09h | UTCMepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial – The Lancet (link to abstract – $ for full-text)
Commentary: Mepolizumab Cuts Exacerbations in Children With Severe Asthma – HealthDay